BioSpace News Archive

DENTSPLY SIRONA Inc., announced that its Board of Directors declared a quarterly cash dividend of $0.11 per share of common stock, an indicated annual rate of $0.44 per share.

BIOASIS TECHNOLOGIES INC. is pleased to announce that all resolutions were passed by requisite majority at its annual general meeting held earlier in New Haven, Conn., United States.

Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 50,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.

Ethos Laboratories, a College of American Pathologists-accredited and a certified leader in diagnostic testing services, announced today the launch of Tru-Immune™ — a finger prick, self-collection kit for its COVID-19 neutralizing antibody test. The simple test allows individuals to safely, quickly, and effectively obt

RODO Medical, Inc., an innovative dental company from San Jose, CA, and ROE Dental Laboratory, a full-service dental laboratory from Independence, OH, announce an exclusive partnership on the distribution and marketing on the FDA-cleared and patented RODO Abutment System for surgically guided full-arch restorations.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the New England Journal of Medicine has published findings from the Phase 3 MOVe-OUT trial evaluating molnupiravir, an investigational oral antiviral medicine, in non-hospitalized high risk adults with mild to moderate COVID-19.

Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its second quarter ended October 31, 2021 .

iECURE today announced that it has entered into an exclusive agreement with the University of Pennsylvania (Penn) to develop next-generation lipid nanoparticles (LNP) for liver gene editing applications.

Synergy HealthCare Alliance (Synergy HCA) is pleased to welcome Real Time Medical Systems (Real Time) as its newest strategic partner.

Tasso, Inc., a leader in clinical-grade blood collection technology, announced that it has completed an oversubscribed $100 million Series B financing round, bringing the total funding to date to $131 million.